Helen Rees, Wits RHI, ECHO Committee Consortium

Wits RHI, ECHO Committee Consortium
Professor Helen Rees is one of South Africa's best respected clinician scientists and is internationally renowned for her research and policy work in HIV, vaccines, reproductive health and drug regulation. She is founder and Executive Director of the Wits Reproductive Health and HIV Institute (Wits RHI) which is the University of Witwatersrand's largest research institution. She is also Personal Professor in the Wits Obstetrics and Gynaecology Department and Co-Director of the Wits African Leadership In Vaccinology Excellence (ALIVE). Helen is an Honorary Professor in the Faculty of Infectious and Tropical Diseases at the London School of Hygiene and Tropical Diseases, an Honorary Fellow of Murray Edwards College, Cambridge University (UK) and an alumnus of Harvard Business School (USA). Helen is Board Chair of the South African Health Products Regulatory Authority (SAHPRA), co-chair of the SA Health Data Advisory and Coordination Committee, member of SA's National Advisory

Presenter Of 1 Presentation

Symposia session

Introduction

Room
Symposia and bridging sessions On-Demand Channel

Moderator Of 1 Session

Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.

Presenter Of 1 Presentation

Symposia session

Introduction

Room
Symposia and bridging sessions On-Demand Channel

Moderator Of 1 Session

Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.

Presenter Of 1 Presentation

Symposia session

Introduction

Room
Symposia and bridging sessions On-Demand Channel

Moderator Of 1 Session

Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.